Chiesi Nederland’s Post

In diabetic management it is a great achievement so far. AI handles the diabetic patient to sleep peacefully .

We are excited to share that we have received CE mark (conformité européene) for our AI-enabled continuous glucose monitoring (CGM) solution. The built-in algorithms offer critical glucose predictions designed to empower people living with #diabetes to proactively intervene when their glucose levels require attention. This milestone brings us one step closer to our commitment to address unmet needs in daily diabetes management. The solution is set to launch in selected European markets in the coming months. #ConnectingWhatCounts #CGM #DiabetesCare https://lnkd.in/eXwZdNE2

Fabry Disease can greatly vary from person to person, making diagnosis challenging. Watch the story from people living with Fabry. In this video you can hear the story from Erica and Annelies, two Dutch patients who talk about their symptoms in the moments that matter. For many years they have been dedicated to underline the symptoms of Fabry in women worldwide. Their story inspires us to continue to strive for providing the best support for people living with Fabry. #FabryAwarenessMonth #SanofiNL https://lnkd.in/e6C7fuPG

It's important that we address not only the medical challenges but also the significant social costs faced by individuals and families living with #rarediseases. By bolstering drug availability and advancing treatments, just #IMAGINE how we can enhance the quality of life for those living with a rare disease. At Chiesi, #WeWontRest until our collective efforts ensure a brighter future for patients, their families and healthcare systems. We will continue to advocate for initiatives that prioritize their interests and pave the way for transformative advancements in healthcare. EFPIA - European Federation of Pharmaceutical Industries and Associations Chiesi Global Rare Diseases #ChiesiGlobalRareDiseases

AIRSUPRA was introduced to the market in January 2024 and achieved sales of USD 7 million in the first quarter of the same year. While AstraZeneca conducted studies on patients as young as 4 years old and adults with asthma aged 18 and above, the FDA granted approval solely for adult patients over 18 years old. However, the company aims to expand the scope of the treatment to include important asthma patient groups in future label updates. At the American Thoracic Society (ATS) conference 2024, AstraZeneca will present an insightful poster titled “P616 - A Bayesian Dynamic Borrowing Approach to Evaluate the Efficacy of Albuterol-budesonide as Needed in Adolescents With Asthma: Design of the Acadia Study'' on May 21 at the San Diego Convention Center, shedding light on the effectiveness of AIRSUPRA (Albuterol-budesonide) in adolescents with asthma. Read detailed insights @ https://lnkd.in/g4rqv-Ev #AIRSUPRA #AstraZeneca #AsthmaTreatment #FDAApproval #MedicalResearch #ATSConference #AdolescentHealth #AcadiaStudy #AlbuterolBudesonide #SanDiegoConventionCenter #HealthcareInnovation

We welcome the news that Boehringer Ingelheim is capping the price of asthma inhalers at $35 a month. https://lnkd.in/gDf97tyh   AAFA continues to work with all stakeholders across the complex U.S. drug pricing ecosystem to ensure that essential medicines are available at an affordable price for those who need them most.   Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex, and often leaves patients with few affordable options.   We will continue to raise awareness of the importance of improving access to treatment by lowering drug costs.   #Asthma #RespiratoryHealth #CommunityHealth #DrugPricing

📢 As we forge ahead, it is crucial to remember that each partner in this journey brings unique strengths. By working in concert, we can strive towards a future where all people living with a #RareDisease have #access to effective #treatment and the hope for a better quality of life.   Read the op-ed our Secretary General, Alexander Natz, wrote for the Rare Disease supplement for The Parliament. Alexander urges a holistic and realistic approach to #OMP reform and action. Such approach must integrate diverse policy solutions under a unified vision through the product lifecycle and should be partnership-driven to transform the landscape of rare disease treatments and #research across #Europe. 👉 https://lnkd.in/dCf3TmNt #RDD2024 #RareDiseaseWeek #OrphanDrugs #Innovation #PatientAccess Takeda EURORDIS-Rare Diseases Europe

What is a happy mouth? Watch this video to learn more. #WorldOralHealthDay 2024

The World Orphan Drug Congress USA is now over for another year, but heeding the insights shared in Boston could yield long-term benefits for patients with rare diseases. Here are four key takeaways to achieve patient access to innovative therapies more quickly and efficiently: 💡 Involve patients actively in defining the new treatment’s value proposition, collaborating with patient organizations at the earliest opportunity. 💡 Start planning HEOR and reimbursement activities far in advance, to identify and generate the evidence package that payers will need to see. 💡 Engage with payers early and often, to educate them on the impact of the disease on patients, the unmet need, and the therapy’s clinical value. 💡 Customize reimbursement proposals to address payers’ specific uncertainties about the product’s value proposition—financial arrangements aren’t “one size fits all”! Didn’t get a chance to meet with me during the Congress? Message me here and we’ll book time to chat about ways STRATENYM can support your market access activities. #WODC #HTA #MarketAccess

🌟 Breaking Barriers: Embracing the Moonshot Initiative in Rare Diseases! 🌙🚀 Exciting news for the rare disease community! We're thrilled to announce that Magda Chlebus, Executive Director Science Policy and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA), a visionary leader in healthcare innovation, will be presenting the groundbreaking Moonshot Initiative at the upcoming International Congress on Rare Diseases and Orphan Drugs. 🎤✨ Unveiling the Moonshot Initiative: 🚀 Mission: The Moonshot Initiative is a bold and transformative approach to addressing the challenges faced by the rare disease community. Magda Chlebus will unveil the mission, strategies, and collaborative efforts that make this initiative a beacon of hope for patients and caregivers. 🌈 Visionary Impact: Explore how the Moonshot Initiative aims to accelerate research, enhance patient care, and foster collaboration among stakeholders. Save the Date: [Friday 1st of March 09.20 – 10.00 AM] 🗓️ Digital How to Tune In: Secure your virtual seat now to witness this groundbreaking presentation. Register and be part of a transformative moment that could shape the future of rare disease interventions. 🔗 [Registrer here: https://bit.ly/3HkkWxA] Spread the Excitement: Tag your colleagues, fellow advocates, and anyone passionate about driving change in the rare disease landscape. Let's amplify the impact of the Moonshot Initiative together! #rarediseasesconference24 #MoonshotInitiative #RareDiseases #HealthcareInnovation #ICORD2023 #PatientAdvocacy Don't miss this extraordinary opportunity to be part of a paradigm-shifting conversation! 🌐🌟